Concepedia

Lack of Efficacy of SGLT2-i in Severe Pneumonia Related to Novel Coronavirus (nCoV) Infection: No Little Help from Our Friends

Antonio Bossi, Franco Forloni, Paolo Luigi Colombelli

Diabetes Therapy · 2020 · 18 citations · 3 references

DOIFull text

Open access

Concepts

References

3

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial

Silvio E. Inzucchi, Bernard Zinman, David Fitchett et al. · Diabetes Care · 2017 · 747 citations

, , +15

Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits

Antonius Baartscheer, Cees A. Schumacher, Rob C. I. Wüst et al. · Diabetologia · 2016 · 652 citations · Full text

, , +16

Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis

Sunder Mudaliar, Sindura Alloju, Robert R. Henry · Diabetes Care · 2016 · 566 citations

, , +17